Orchard Therapeutics Reports Third Quarter 2019 Financial Results and Achievement of Key 2019 Milestones for Neurometabolic and Primary Immune Deficiencies Franchises
November 06, 2019 16:01 ET | Orchard Therapeutics (Europe) Limited
ASH Abstracts Published Today Confirm Achievement of All Key Endpoints in Wiskott-Aldrich Syndrome Registrational Trial and Demonstrate Consistency of Data Between the Fresh and Cryopreserved...
Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting
November 06, 2019 09:00 ET | Orchard Therapeutics (Europe) Limited
Registrational Trial for Wiskott-Aldrich Syndrome Met Key Primary and Secondary Endpoints at Three Years; Data from Integrated Analysis Reinforce Treatment Benefits of Gene Therapy and Durability of...
Orchard Therapeutics to Webcast Conference Call of Third Quarter 2019 Financial Results
October 30, 2019 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Presents Data from OTL-200 in Patients with Metachromatic Leukodystrophy Using Cryopreservation
October 22, 2019 07:00 ET | Orchard Therapeutics (Europe) Limited
Stable Levels of Engraftment and Reconstitution of Enzyme Activity in Patients with Up to 12 Months of Follow-up Indicate Similar Profiles Between Cryopreserved and Fresh Formulations Regulatory...
Orchard Therapeutics Announces Appointment of CEO Mark Rothera to The Alliance for Regenerative Medicine’s 2020 Board of Directors
October 02, 2019 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of...
Orchard Therapeutics Announces Presentation of New Clinical Data for OTL-200 for Metachromatic Leukodystrophy at Upcoming European Society of Gene & Cell Therapy Annual Congress
September 30, 2019 07:00 ET | Orchard Therapeutics
BOSTON and LONDON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics to Present at the 2019 Cell & Gene Meeting on the Mesa
September 25, 2019 07:00 ET | Orchard Therapeutics
BOSTON and LONDON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Announces Departure of Chief Commercial Officer
September 13, 2019 07:00 ET | Orchard Therapeutics
BOSTON and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of...
Orchard Therapeutics Announces Encouraging Update from Proof-of-Concept Study of OTL-203 for the Treatment of Mucopolysaccharidosis Type I (MPS-I)
September 04, 2019 07:05 ET | Orchard Therapeutics
Six of Eight Patients Treated to Date with Follow-up Out to 12 Months in First Patient to Receive Treatment Evidence of Engraftment and Peripheral Blood Alpha-L-iduronidase (IDUA) Enzyme...
Orchard Therapeutics Presents an Integrated Data Analysis Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of Metachromatic Leukodystrophy
September 04, 2019 07:00 ET | Orchard Therapeutics
Further Demonstration that OTL-200 Provides Meaningful Clinical Benefit on Cognitive and Motor Function No Standard Treatment Options Available, Regulatory Submission in Europe Planned for First Half...